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Abstract 
Background: Between the publication of the Union of International Cancer Control staging 
system (UICC) 7th and 8th editions, other staging algorithms for oropharyngeal squamous cell 
carcinoma (OPSCC) were proposed from Radiation Therapy Oncology Group (RTOG), MD 
Anderson Cancer Center (MDACC), and Yale University. 
Methods: With C-statistics, the above-mentioned 5 staging algorithms were compared for overall 
and relapse-free survival endpoints in a multi-institutional cohort of OPSCC cases (n=338) treated 
with primary surgery. 
Results: Pathological UICC 8th ed yielded the highest C-indexes in the entire cohort and in the 
HPV- subset, whereas MDACC was superior for HPV+ OPSCC. RTOG was the simplest and 
holistic algorithm with a non-inferior discriminatory power. 
Conclusion: UICC 8th ed, MDACC and RTOG offer moderate and comparable efficacy for staging 
in this OPSCC patient cohort undergoing surgical treatment. Notable discrepancy between clinical 
and pathological UICC 8th ed algorithms poses potential concerns in diagnosis, treatment, research 
and data management. 
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Introduction 
Human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma (OPSCC) is 
known to have a better prognosis compared to its smoking and alcohol associated counterpart1,2. 
This prominent difference was shown in multiple series treated either with primary surgery3,4 or 
primary (chemo)radiotherapy ((C)RT)5,6. In 2010, Ang et al. proposed a new staging system based 
on a recursive partitioning analysis (RPA) done on a prospective randomized Radiation Therapy 
Oncology Group (RTOG) 0129 trial population with specific eligibility criteria5. This was the first 
classification which was taking the HPV status into consideration. Since then, various staging 
systems including HPV status were proposed with the main aim of improving the risk stratification 
for a better estimation of prognosis compared to Union of International Cancer Control staging 
system (UICC) 7th ed7. 
The UICC 8th ed was implemented in January 20178. The new OPSCC staging is separated based 
on HPV status. For the HPV associated patients, the International Collaboration on Oropharyngeal 
Cancer Network Staging (ICON-S) was chosen for the clinical staging (cUICC). This staging 
algorithm was first developed in Canada9 and validated in multiple centres from North America 
and northern Europe6. In these training and validation cohorts, only 2% of the patients were treated 
surgically. On the other hand, the development of the pathological staging was based on a 
retrospective multicentre study on patients mainly treated in North America and United 
Kingdom10. Of note, this pathological staging was not systematically validated such as the clinical 
staging algorithm at the time of implementation into the UICC 8th ed. Furthermore, the 
classification of nodal staging for all head and neck cancer subsites except for HPV associated 
OPSCC was based on a large dataset of oral cavity tumours8. 
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In conclusion, it remains unclear, whether the UICC 8th ed can be applied in different areas of the 
world. Including this staging system, most recently proposed staging algorithms are heavily based 
on North American patient data mostly treated with primary (C)RT5,6,10–13. However, smoking, 
alcohol consumption and sexual habits and prevalence rates of HPV associated and non-HPV 
associated OPSCC are strongly dependent on geography. Even among developed countries, these 
rates vary substantially14–18. Therefore, the prognostic stratification power of a staging system 
developed in a population may vary elsewhere19. Despite the remaining importance and high 
prevalence rates of non-HPV associated OPSCC, the contrast between the abundance of literature 
about HPV associated OPSCC and the scarcity of published works about non-HPV associated 
OPSCC in the last decade is striking. Among many proposed staging algorithms for OPSCC, only 
the RTOG and Dutch systems covered both non-HPV and HPV associated OPSCC5,13,20, whereas 
no new algorithm was proposed specifically for non-HPV associated OPSCC. Also in terms of 
differences in treatment modality, it is possible that a prognostic risk classification derived from a 
(C)RT cohort may perform worse than expected in a surgical cohort10. 
With this background, our aims were to (1) compare the prognostic qualities of 5 contemporary 
staging systems which were published until the official release of UICC 8th ed; (2) test their 
applicability in terms of risk prognostication; and (3) investigate the rates of inter- and intra-stage 
migration21 among and within the c/pUICC 7th and 8th editions, respectively in our multi-
institutional cohort treated by primary surgery. 
Materials and Methods 
A cohort of 338 patients diagnosed with OPSCC in 7 participating centres were included in the 
analysis. The ethics committee of St. Gallen centrally approved the study protocol for all 
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participating centres (reference number: 12/106/L), and the study was performed in accordance 
with the Declaration of Helsinki. Due to its retrospective design, it was not feasible and, therefore, 
not requested by the ethics committee to obtain written informed consent of each study participant. 
All patients were treated with primary surgery with or without adjuvant treatment based on the 
presence of pathological risk factors. Details of patient characteristics, diagnostic and treatment 
procedures were published in a previous paper4. To optimize the diagnostic accuracy for HPV 
status, both p16 and HPV DNA positivity was sought as reported in the literature13,22. A tumour 
was defined as HPV+ only if immunohistochemical p16 overexpression and HPV high risk type 
DNA by PCR were detected. 
Proposed systems other than UICC were chosen, if they met the following criteria: published 
before 2018, clearly proposed as a staging algorithm by the authors, not being a preliminary 
version of a later modified algorithm from the same working group, relied on variables which were 
available in our cohort. Concerning the latter criteria, some models included variables like co-
morbidity, non-standard definition for smoking, haemoglobin level, values of epidermal growth 
factor receptor overexpression, maximum 18F- fluorodeoxyglucose standard uptake which were 
absent in our database13,20,23–26. The remaining eligible systems were tested: c/pUICC 7th and 8th 
editions, RTOG classification5, MD Anderson Cancer Centre (MDACC)11 and Yale University12 
staging systems. 
All staging algorithms were compared with Harrell’s Concordance-index (C)27 for the co-primary 
endpoints of overall survival (OS) and recurrence-free survival (RFS). C-statistics were computed 
using the Inference of C function (Inf. Cval) of the survC1 package for the R language. The 
number of iterations of perturbation-resampling was set to the default of 1000. Additionally, 
hazard ratios (HR) for OS and RFS were computed using a cox proportional hazards regression 
model implemented in the coxph function of the survival package in the R language. The adjusted 
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model compensates for smoking above 10 pack years (py), age and extracapsular extension (ECE). 
The influences of those confounding variables for both endpoints were also reported separately. 
Due to missing data, alcohol consumption habits were not analysed as a confounding variable. The 
Student's t-test was used for mean comparison, the Wilcoxon rank-sum test for median comparison 
and the chi-squared test for categorical variables. Finally, the stage migration effect between the 
UICC 7th and 8th ed and the agreement among clinical and pathological ECE (cECE and pECE, 
respectively) were compared both descriptively and by means of Cohen’s weighted kappa. All tests 
were two-tailed and p values < 0.05 were judged as statistically significant. The anonymised 
version of the data is available upon reasonable request to the corresponding author. 
Results 
Patient and disease characteristics as well as the corresponding differences between HPV+ and 
HPV- subgroups are provided in Table 1. Between patients with HPV+ and HPV- OPSCC, 
statistically significant discrepancies were observed in smoking and alcohol consumption habits, 
cECE and adjuvant treatment indication. After the post-operative pathological examination for 
pECE, the previously statistically significant difference in ECE between HPV+ and HPV- patients 
disappeared. Contrary to expected, there was no significant age difference among patients 
diagnosed with HPV+ and HPV- OPSCC. 
Regardless of HPV status, concordance between cUICC and pUICC was higher within the 7th 
edition compared to the 8th ed (Table 2). In the 8th ed, pathology examination resulted in an up-
staging rate of 19.4% in HPV-, and a down-staging rate of 45.4% in HPV+ patients. 
Concerning the inter-staging discordance, cUICC from the 7th to the 8th edition yielded a modest 
up-staging rate of 8.6% in HPV-, and a high down-staging rate of 93.9% in HPV+ patients. 
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Similarly, pathological stage migration from 7th to the 8th ed manifested as up-staging in 21.1% of 
HPV-, and as down-staging in 92% in HPV+ patients (Table 3). 
Cohen’s weighted kappa coefficients for the inter-agreement of the above-mentioned parameters 
are found in the Supplementary Table S1. 
Overall Survival 
When the entire cohort was evaluated, the C-indexes revealed a higher prognostic accuracy for 
RTOG, cUICC and pUICC 8th ed in an increasing order, compared to UICC 7th ed (Table 4). 
Almost no difference was observed in the HPV- patients between 7th and 8th ed of both cUICC and 
pUICC. In HPV+ patients, pUICC 8th ed was superior to pUICC 7th ed, whereas no improvement in 
prognostic accuracy was observed in cUICC versions. Despite an improvement within the pUICC 
(from 7th to 8th ed), both pUICC editions fell short of both cUICC editions for HPV+ OPSCC. 
MDACC slightly outperformed the remaining staging algorithms for HPV+ OPSCC. The RTOG 
classification markedly lost its prognostic power when it was applied separately on HPV+ and 
HPV- groups (Table 4). Adjusted and unadjusted ordinal HRs with 95% confidence intervals (CI) 
for death are provided in Table 5. Corresponding categorical HRs can be found in the 
Supplementary Table S2. For the entire cohort, RTOG, cUICC 8th ed and pUICC 8th ed yielded 
statistically significant HRs for OS, with the highest observed in RTOG. For the HPV+ and HPV- 
OPSCC, no staging system showed any statistically significant risk stratification. 
Recurrence-free Survival 
In the entire cohort, RTOG, cUICC and pUICC 8th ed outperformed the cUICC and pUICC 7th ed 
based on C-statistics (Table 4). There was no difference between the RTOG and cUICC 8th ed, 
whereas pUICC 8th ed showed a marginal benefit. For the HPV- patients, no meaningful difference 
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was observed among any staging systems. In the HPV+ group, an increasing prognostic power in 
the following order was observed: cUICC 7th ed, pUICC 7th ed, Yale, cUICC 8th ed, pUICC 8th ed 
and MDACC. As observed for the OS endpoint, RTOG lost its prognostic power for RFS when 
separately applied on HPV+ and HPV- groups (Table 4). Adjusted and unadjusted ordinal HRs for 
recurrence or death are provided in Table 6. Corresponding categorical HRs are outlined in the 
Supplementary Table S3. For the whole cohort, RTOG, cUICC 8th ed and pUICC 8th ed yielded 
statistically significant HRs for RFS, with the highest observed in RTOG. In the HPV+ group, 
pUICC 8th ed, MDACC and Yale showed statistically significant HRs. However, only pUICC 8th ed 
remained statistically significant as the model was adjusted for risk factors. No staging system 
showed any statistically significant risk stratification in the HPV- group. 
In terms of predefined potential confounding variables in the entire cohort, smoking > 10 py and 
cECE+ had a significant negative impact on both OS (HR: 2.33 [95% CI: 1.31 - 4.13], p<0.01 and 
HR: 1.67 [95% CI: 1.00 – 2.78], p=0.049, respectively) and RFS (HR: 1.76 [95% CI: 1.11 – 2.78], 
p=0.02; HR: 1.77 [95% CI: 1.13 – 2.76], p=0.01, respectively). For HPV+ OPSCC, smoking > 10 
py and cECE+ were significantly associated with worse OS (HR: 2.67 [95% CI: 1.09 – 6.58], 
p=0.03) and RFS (HR: 2.15 [95% CI: 1.06 – 4.32], p=0.03), respectively. For HPV- OPSCC, 
cECE+ had a significant negative impact on OS (HR: 2.28 [95% CI: 1.18 – 4.40], p=0.01) and RFS 
(HR: 2.16 [95% CI: 1.18 – 3.94], p=0.01), whereas pECE+ was only significantly associated with 
worse OS (HR: 1.91 [95% CI: 1.12 – 3.26], p=0.02). The effects of possible confounding variables 
of age, smoking and ECE on OS and RFS are given in the Supplementary Table S4. 
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Discussion 
Similar to non-surgical therapies, primary surgery demonstrates a superior outcome in HPV+ 
OPSCC compared to its HPV- counterpart3,4,28–33. Although no currently established single 
standard for the treatment of OPSCC exists, there are numerous ongoing trials about treatment de-
intensification in HPV+ OPSCC34 and comparison of surgery and radiotherapy in terms of 
functional outcome (EORTC Best-of trial NCT02984410), for which an accurate staging plays a 
key role for risk stratification. As already mentioned, the increasing academic interest in HPV+ 
OPSCC and diminishing interest in HPV- OPSCC can only be partially justified with the change in 
epidemiology mainly in the developed world. The majority of OPSCC cases worldwide are still 
HPV- and mainly attributed to tobacco and alcohol exposure. 
To our knowledge, this is the first study comparing the recently proposed staging systems besides 
UICC in a cohort consisting of both HPV+ and HPV- OPSCC, all treated by surgery as the primary 
treatment modality. Recently, Mizumachi et al. applied the cUICC 8th to a cohort (n=195) of 
HPV+ and HPV- OPSCC patients treated with a heterogeneous treatment approach consisting of 
primary surgery or (C)RT19. They concluded that the 8th edition is more suitable for Japanese HPV- 
OPSCC patients. A similar study with a mixed cohort from Germany (n=561)17 came to the 
opposite conclusion, indicating a better prognostic stage discrimination of the 8th edition for HPV+ 
OPSCC, which is in line with our findings. 
Our results demonstrated a higher rate of ECE+ lymph node metastases of HPV+ OPSCC 
compared to HPV- cases. Moreover, the underestimation of cECE+ by imaging modalities was 
more prominent in HPV+ OPSCC. The specificity and sensitivity to accurately diagnose the 
presence of cECE+ with different imaging modalities vary between 70% and 90%35. Furthermore, 
a low intra- and inter-observer agreement can pose problems for clinical diagnosis36.  
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Due to major differences in the c/pN and c/pUICC of the 8th edition, we observed a high rate of 
post-surgical stage migration within the 8th edition compared to the 7th edition of UICC. This stage 
migration phenomenon is an expected result, and has been recently reported as down-staging in 
HPV+ OPSCC only cohorts19,37. On the other hand, the more than double surgical up-staging rate 
within the 8th vs. 7th edition (19.4% vs. 8.6%) in our HPV- patients is mainly caused by the 
incorporation of ECE status into the nodal staging system of UICC 8th ed. 
The inter-stage migrations from the 7th to 8th editions in HPV+ and HPV- OPSCC to opposite 
directions in our series confirm the intention to widen the prognostic gap between two entirely 
different diseases. HPV+ cases underwent a dramatic down-staging both in clinical (93.9%) and 
pathological (92%) stages, whereas HPV- cases showed a rather modest up-staging pattern in 
clinical (8.6%) and pathological (21.1%) classifications. Except for one patient, all inter-stage 
migrations in HPV+ and HPV- subsets were unidirectional. The similarity between our inter-stage 
migration rates to a National Cancer Database study (n=6465)38 is striking: in HPV+ OPSCC, 
clinical 93.9% / 93.9% and pathological 92% / 91.7% down-staging, respectively. 
Except for the ICON-S (i.e. cUICC 8th ed) which partially contained patients from northern Europe, 
all remaining staging algorithms were developed on cohorts diagnosed and treated in North 
America. Moreover, it is worth to note that the UICC 8th ed for HPV- OPSCC is based on a North 
American oral cavity data8. The comparison of 5 different staging algorithms in our cohort 
confirmed the applicability and moderate superiority of pUICC 8th ed for the OS estimation of 
HPV- OPSCC patients. For the estimation of RFS, RTOG and cUICC 8th ed demonstrated 
comparable prognostic accuracy, and pUICC 8th ed only showed a marginal benefit over them. 
When our cohort was separated by HPV status, only a slight improvement was revealed by the 
UICC 8th ed for HPV+ OPSCC, as the cUICC and pUICC 8th ed showed a moderately better 
accuracy to its previous edition and Yale, respectively. On the other hand, all of them were 
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outperformed by MDACC. For the HPV- OPSCC, no substantial improvement was observed with 
the newer systems. 
The prognostic power of the RTOG deserves a careful interpretation. Since it is a three-tiered 
system which is largely separated by HPV and smoking status, two important problems arise when 
it is used in a purely HPV+ or HPV- cohort. First, it gets curbed down to a two-tiered system. 
Then, an imbalanced patient distribution (and therefore a lack of events) occurs between the 
intermediate and low (if HPV+) or high (HPV-) risk groups. Therefore, RTOG seems to be only 
useful when used as a holistic staging system. In terms of RFS estimation, RTOG offers a more 
practical solution than the more complicated c/pUICC 8th ed, which is even not consistent within 
itself (discordance in clinical and pathological classifications). If, on the other hand, a higher 
prognostic accuracy is deemed as a more important factor than practicability, MDACC offers an 
even higher accuracy than UICC with a less complicated and one-stop solution. However, it is 
worth to note that none of RTOG, MDACC or pUICC 8th ed was validated until the UICC 8th ed 
was released. Moreover, investigators from John Hopkins Hospital recently compared the cUICC 
8th ed and MDACC in a cohort of HPV+ OPSCC where 38% of the patients were treated with 
primary surgery. Contrary to our findings, they showed a superior risk stratification of the cUICC 
8th ed over MDACC both for OS and RFS39. This difference to our findings may be caused by 
geographical factors, difference in primary treatment modalities, as well as due to the fact that the 
cUICC 8th ed and MDACC were developed on cohorts treated with (C)RT. 
We also evaluated the prognostic impact of age, smoking status and ECE as well-established risk 
factors in the literature. Age was not a statistically significant prognostic factor. In the entire 
cohort, smoking above 10 py revealed a statistically significant impact on OS and RFS. This effect 
remained statistically significant for OS in the HPV+ patients. The loss of its significance for the 
HPV- OPSCC can be explained by 92% of our HPV- OPSCC cases being heavy smokers. In the 
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literature, there are contradicting reports about the prognostic impact of tobacco exposure on 
HPV+ OPSCC5,17.  
In our series, a negative prognostic impact of pECE+ on OS was only observed in HPV- OPSCC 
cases. This finding is in agreement with some of the previously published literature35,40 showing 
the lack of prognostic value of ECE status in HPV+ OPSCC, whereas contradicting evidence also 
exists37,38,41. Interestingly, cECE demonstrated a statistically significant impact on both endpoints 
of OS and RFS except for the HPV+ OPSCC patients’ OS. This may be a result of either a type I 
error, or an unconventional hypothesis-generating finding worth to be investigated further: The 
incidence of ECE+ is correlated with lymph node size42. Another fact is the prognostic impact of 
volumetric burden of the disease43,44. Therefore, it is possible that the volumetric nodal burden of 
the disease actually plays a more important role than the ‘true’ pECE, and ECE is a rather 
surrogate marker for nodal volume, and not necessarily vice versa. 
It is important to emphasize that a C-index of 0.5 means that a prognostic model does not have a 
discriminatory power better than coincidence, and an index of 1 indicates an ideal model. In our 
current findings, the C-indexes vary between 0.45 and 0.64 which do not suggest a convincingly 
high prognostic accuracy. Nevertheless, it is interesting to witness the proclamation of marginal 
benefits for prognostic ability in the magnitude of 0.003 (C-index) as “improvements” in the 
literature45. As we see from cross-validation studies, even an externally validated system may not 
yield the same value in another cohort and can be outperformed by another staging algorithm12,26. 
As the UICC staging committee members correctly pointed out, not only the prognostic accuracy, 
but also the practicality, physician compliance and worldwide applicability belong to the important 
aspects of an ideal staging system8. Although we value and respect the effort put forward by the 
UICC committee, in the light of the recently available data and based on our everyday experience, 
we fail to recognise those principles implemented in the UICC 8th ed. As reproduced in our study, 
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both clinical and pathological staging algorithms of UICC 8th ed have a higher or at least non-
inferior prognostic value compared to other proposed and previously existing staging systems. As 
demonstrated in the literature and confirmed by our data, there is a ≥90% down-staging of HPV+ 
OPSCC with UICC 8th compared to 7th ed. Although we would like to de-intensify the treatment of 
those patients, the phase III treatment de-intensification trials for HPV+ OPSCC are ongoing, and 
the current treatment indications are still not based on HPV or any other risk-stratification 
introduced by the UICC 8th edition, which is based on the analyses of retrospective data of patients 
who were treated with conventional algorithms and guidelines. Currently, it is questionable, what 
kind of a practical consequence except for a more complex staging experience the UICC 8th ed, 
especially the pUICC will bring in everyday practice. The discrepancy between clinical and 
pathological staging algorithms is a known issue since the earlier versions of UICC46. However, 
with the UICC 8th ed, this gap due to intra-stage migration became vivid. In other words, even 
without gaining any new information through surgery (i.e. same post-operative pathological 
tumour and nodal features as clinically identified via imaging, endoscopy and manual 
examination), different clinical and pathological stages can be assigned to the very same patient. It 
is quite unconventional and counterintuitive to see a head and neck cancer patient not only 
differently staged but also differently processed for staging, only due to the chosen treatment 
modality. This poses potential concerns in diagnosis41, treatment, research and data management. 
Our study has its limitations. Despite being quite homogenous, the cohort carries the intrinsic 
potential source of bias due to its retrospective nature. Furthermore, during the development of the 
compared staging systems, different definitions for HPV status concerning p16 IHC and/or HPV 
DNA had been used, impairing the possibility to compare them. 
In conclusion, with each of their strengths and weaknesses, the UICC 8th ed, MDACC and RTOG 
systems offer moderate efficacy in similar magnitudes as staging algorithms for patients diagnosed 
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with OPSCC undergoing surgical treatment. Building complex models only to achieve a marginal 
benefit is a futile effort. Beyond an acceptable risk stratification accuracy, pursuing practical utility 
should be the primary goal of developing future algorithms of the UICC, as the internationally 
accepted authority for cancer staging. 
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Table 1: Patient and disease characteristics 
 Total HPV- HPV+ p-value 
n (%) 338 175 (51.8) 163 (48.2)  
Gender: female (%) 95 (28.1) 44 (25.1) 51 (31.3) 0.256 
Mean age (standard deviation) 68.4 (9.8) 67.8 (8.9) 69.2 (10.7) 0.196 
Median age (interquartile range) 69 (62, 75) 69 (62, 72.5) 68 (62, 76) 0.341 
Subsite (%)    <0.001 
 - Base of tongue 60 (17.8) 37 (21.1) 23 (14.1)  
 - Pharyngeal wall 16 (4.7) 15 (8.6) 1 (0.6)  
 - Soft palate 27 (8) 24 (13.7) 3 (1.8)  
 - Tonsil 235 (69.5) 99 (56.6) 136 (83.4)  
Adjuvant treatment (%) 223 (66) 99 (56.6) 124 (76.1) <0.001 
Smoking > 10 py (%) 240 (71) 161 (92) 79 (48.5) <0.001 
Alcohol ≥3 units* (%)    <0.001 
 - Missing 38 (11.2) 14 (8) 24 (14.7)  
 - No 177 (52.4) 72 (41.1) 105 (64.4)  
 - Yes 123 (36.4) 89 (50.9) 34 (20.9)  
cECE+ (%) 55 (16.3) 21 (12) 34 (20.9) 0.040 
pECE+ (%) 98 (29) 44 (25.1) 54 (33.1) 0.134 
*: 3 dL beer or 1 dL wine or 4 cL spirit per day 
cECE: clinical extracapsular extension; pECE: pathological extracapsular extension; py: pack-years 
 
Table 2: Agreement of the clinical and pathological classifications within each UICC edition 
7th edition Concordant % Up-staging % Down-staging % N total 
All 285 84.3 27 8.0 26 7.7 338 
HPV+ 137 84.0 12 7.4 14 8.6 163 
HPV- 148 84.6 15 8.6 12 6.9 175 
8th edition        
All 213 63.0 38 11.2 87 25.7 338 
HPV+ 85 52.1 4 2.5 74 45.4 163 
HPV- 128 73.1 34 19.4 13 7.4 175 
 
 
Table 3: Rates of stage migration from UICC 7th to 8th edition 
Clinical Concordant % Up-staging % Down-staging % N total 
All 169 50.0 15 4.4 154 45.6 338 
HPV+ 10 6.1 0 0.0 153 93.9 163 
HPV- 159 90.9 15 8.6 1 0.6 175 
Pathological        
All 151 44.7 37 10.9 150 44.4 338 
HPV+ 13 8.0 0 0.0 150 92.0 163 
HPV- 138 78.9 37 21.1 0 0.0 175 
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Table 4: C-statistics for overall and recurrence-free survival 
Staging Full cohort HPV+ HPV- 
Overall Survival 
cUICC 7th ed 0.45 (0.34 to 0.56) 0.58 (0.33 to 0.82) 0.56 (0.40 to 0.72) 
pUICC 7th ed 0.46 (0.37 to 0.56) 0.48 (0.33 to 0.63) 0.59 (0.39 to 0.78) 
cUICC 8th ed 0.62 (0.52 to 0.72) 0.58 (0.29 to 0.87) 0.57 (0.41 to 0.73) 
pUICC 8th ed 0.64 (0.55 to 0.74) 0.55 (0.41 to 0.68) 0.60 (0.41 to 0.79) 
RTOG 0.61 (0.52 to 0.69) 0.50 (0.44 to 0.56) 0.52 (0.48 to 0.57) 
MDACC  0.61 (0.42 to 0.80)  
Yale  0.53 (0.37 to 0.69)  
Relapse-free Survival 
cUICC 7th ed 0.50 (0.43 to 0.57) 0.52 (0.36 to 0.68) 0.52 (0.42 to 0.63) 
pUICC 7th ed 0.51 (0.43 to 0.59) 0.53 (0.37 to 0.70) 0.53 (0.42 to 0.63) 
cUICC 8th ed 0.58 (0.52 to 0.64) 0.55 (0.37 to 0.74) 0.53 (0.41 to 0.66) 
pUICC 8th ed 0.59 (0.53 to 0.65) 0.56 (0.49 to 0.64) 0.54 (0.41 to 0.67) 
RTOG 0.58 (0.52 to 0.64) 0.49 (0.45 to 0.53) 0.51 (0.47 to 0.55) 
MDACC  0.60 (0.46 to 0.73)  
Yale  0.54 (0.42 to 0.66)  
The 95% confidence intervals are shown in parentheses. 
 
Table 5: Unadjusted and adjusted ordinal hazard ratios for death 
Staging Hazard ratio p Adjusted hazard ratio p 
Full Cohort     
cUICC 7th ed 0.99 (0.81 to 1.21) 0.956 0.98 (0.79 to 1.20) 0.820 
pUICC 7th ed 0.99 (0.82 to 1.20) 0.920 0.95 (0.76 to 1.18) 0.627 
cUICC 8th ed 1.42 (1.19 to 1.68) <0.001 1.29 (1.07 to 1.55) 0.008 
pUICC 8th ed 1.40 (1.22 to 1.61) <0.001 1.33 (1.13 to 1.56) <0.001 
RTOG 1.68 (1.30 to 2.17) <0.001 1.79 (1.26 to 2.55) 0.001 
HPV+     
cUICC 7th ed 1.15 (0.71 to 1.87) 0.562 1.14 (0.69 to 1.87) 0.608 
pUICC 7th ed 0.93 (0.61 to 1.44) 0.754 0.99 (0.61 to 1.61) 0.963 
cUICC 8th ed 1.20 (0.57 to 2.52) 0.638 1.08 (0.52 to 2.21) 0.842 
pUICC 8th ed 1.59 (0.70 to 3.59) 0.266 1.66 (0.72 to 3.85) 0.237 
RTOG 1.32 (0.48 to 3.63) 0.592 0.85 (0.28 to 2.55) 0.773 
MDACC 1.47 (0.89 to 2.42) 0.128 1.30 (0.77 to 2.17) 0.324 
Yale 1.24 (0.76 to 2.02) 0.381 1.22 (0.76 to 1.94) 0.408 
HPV-     
cUICC 7th ed 1.12 (0.89 to 1.40) 0.344 0.99 (0.77 to 1.26) 0.914 
pUICC 7th ed 1.15 (0.93 to 1.43) 0.198 1.01 (0.79 to 1.31) 0.921 
cUICC 8th ed 1.15 (0.93 to 1.42) 0.188 1.15 (0.93 to 1.42) 0.197 
pUICC 8th ed 1.19 (0.98 to 1.43) 0.075 1.03 (0.79 to 1.34) 0.829 
RTOG 0.57 (0.26 to 1.25) 0.163 0.55 (0.25 to 1.21) 0.138 
The 95% confidence intervals are shown in parentheses. 
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Table 6: Unadjusted and adjusted ordinal hazard ratios for recurrence or death 
Staging Hazard ratio p Adjusted hazard ratio p 
Full Cohort     
cUICC 7th ed 0.93 (0.78 to 1.10) 0.393 0.90 (0.75 to 1.07) 0.221 
pUICC 7th ed 0.90 (0.76 to 1.06) 0.202 0.85 (0.70 to 1.03) 0.092 
cUICC 8th ed 1.29 (1.11 to 1.50) 0.001 1.19 (1.01 to 1.39) 0.035 
pUICC 8th ed 1.27 (1.12 to 1.43) <0.001 1.22 (1.06 to 1.41) 0.005 
RTOG 1.51 (1.22 to 1.87) <0.001 1.66 (1.23 to 2.25) 0.001 
HPV+     
cUICC 7th ed 1.05 (0.73 to 1.50) 0.797 1.03 (0.72 to 1.48) 0.865 
pUICC 7th ed 0.88 (0.63 to 1.22) 0.435 0.85 (0.59 to 1.22) 0.381 
cUICC 8th ed 1.51 (0.82 to 2.77) 0.189 1.37 (0.76 to 2.46) 0.301 
pUICC 8th ed 1.99 (1.11 to 3.56) 0.020 1.99 (1.09 to 3.64) 0.025 
RTOG 1.04 (0.45 to 2.40) 0.923 0.88 (0.34 to 2.27) 0.792 
MDACC 1.57 (1.05 to 2.37) 0.030 1.44 (0.95 to 2.18) 0.082 
Yale 1.50 (1.03 to 2.19) 0.036 1.42 (0.98 to 2.06) 0.062 
HPV-     
cUICC 7th ed 1.00 (0.82 to 1.23) 0.968 0.89 (0.71 to 1.11) 0.299 
pUICC 7th ed 1.00 (0.83 to 1.22) 0.959 0.90 (0.72 to 1.14) 0.379 
cUICC 8th ed 1.06 (0.87 to 1.28) 0.571 1.06 (0.88 to 1.28) 0.551 
pUICC 8th ed 1.05 (0.89 to 1.25) 0.547 0.92 (0.72 to 1.16) 0.470 
RTOG 0.79 (0.36 to 1.73) 0.561 0.76 (0.35 to 1.66) 0.497 
The 95% confidence intervals are shown in parentheses. 
 
